ABOUT US

LIGHTHOUSE offers complete solutions for headspace Oxygen Monitoring, Container Closure Integrity Testing, Moisture Determination and Microbial Contamination inspection of media vials. Our solutions include feasibility studies, process and packaging studies, method development, method validation protocols, automated or benchtop lease platforms, on-site trouble shooting and support.

Rapid, nondestructive, laser-based headspace analysis is suitable for applications specific to the sterile pharmaceutical industry. It is a useful analytical tool to generate statistical process and product data in all stages of the product life cycle, from Development to Manufacturing and Quality Control. LIGHTHOUSE Instruments is the leading provider and manufacturer of headspace analysis platforms and measurement services.

Contact us for a free demo, feasibility study, or other information.

SOLUTIONS AND SERVICES

Opportunities for improving and streamlining the media fill process are interesting for aseptic filling operations. In particular, the manual visual inspection process used to inspect media vials for signs of contamination after incubation is considered to be tedious and time-consuming.

This collaborative automated sample handler eliminates manual sample handling enabling testing of large sample sets and collection of statistically significant data, while freeing analyst’s time. The FMS Automation Module has a sample capacity of hundreds of vials and can complete headspace testing with a throughput as high as 300 samples per hour.

The PULSAR Headspace Inspection System can provide automated, 100% inspection of headspace oxygen, pressure, and carbon dioxide levels in sealed parenteral containers, while our PULSAR Headspace CCI Inspection Lease System offers a small footprint, fast delivery solution for the 100% CCI inspection of pharmaceutical product on a per project basis.

Explore a development lab and the various areas where headspace analysis can be used to generate robust, science-based data on packages and processes in this self-guided, virtual tour.

The revised EU Annex 1 contains new requirements for ensuring the container closure integrity (CCI) of sterile pharmaceutical products, causing pharmaceutical companies to reassess their CCI policies for compliance.

What is your Container Closure Integrity (CCI) strategy? Recent regulatory revisions have put emphasis on appropriately designed CCI studies and robust method validation. LIGHTHOUSE offers complete solutions for CCI testing throughout the product life cycle, from Development to Manufacturing and Quality Control. 

WEBINARS

Explore the limitations of traditional moisture determination techniques, an innovative approach using laser-based headspace analysis, and real-world case studies using this non-destructive method.

Discover the power of headspace gas ingress in ensuring product quality. Dr. Derek Duncan, Director of Product Lines, Lighthouse Instruments, reveals the golden tool for container closure integrity testing.

Gain insight into the technical and regulatory justification for adding water activity measurements into pharmaceutical stability protocols.

Gain insight into the risk to container closure integrity (CCI) during deep cold storage and identify appropriate analytical tools, to generate robust data to characterize and mitigate the risk to CCI.

This webinar reviews how oxygen levels in finished parenteral drug containers can be determined and controlled throughout the product life cycle by using laser-based headspace analysis.

Recent regulatory guidance has triggered changes in industry best practices in the area of container closure integrity (CCI) testing. A more science-based holistic approach that includes robust design & qualification of the process and the implementation of appropriate process controls is required. This webinar will describe a framework to enable such a holistic approach to CCI that assures both the primary packaging and the process contribute to good CCI of sterile injectable vial product.

Deep cold storage, at dry ice (-80°C) or even cryogenic (-196 °C) temperatures, poses a significant challenge to packaging components and can result in CCI failures.

Water activity determination is increasingly being used in the pharmaceutical industry as evidenced by a newly drafted USP <922&GT Chapter for Water Activity measurement. This webcast presents how a water activity measurement can be implemented to give insight into the impact of moisture on critical product quality attributes including stability, dissolution rate, and physical properties of tablets, pills, capsules, and other solid pharmaceutical material.

Imagine a blue dye test, but replace the dye with a tracer gas. Headspace Gas Ingress Testing is a robust detection method of critical leaks. It is a rapid, non-destructive, analytical measurement and can be scientifically validated. Are you considering to upgrade your blue dye test, and do you want to learn more about this approach? Watch this webinar.

This webinar describes the use of positive controls as an important element of CCI studies designed to validate packaging components for CCI or to qualify processes for producing good CCI.

This webinar presents how to design and conduct studies to assess the total oxygen permeation rate of your pre-filled syringes, and how to determine if the permeation is primarily through the plunger or through the tip.  Protecting oxygen-sensitive formulations during filling will also be discussed. 

This webinar describes how non-destructive headspace moisture analysis can be used for characterizing batch moisture distributions, for lyo cycle development and optimization, and for freeze dryer moisture mapping and validation.

This webinar will review how oxygen levels in finished parenteral drug containers can be determined and controlled throughout the product life cycle by using laser-based headspace analysis.

The new language in EU Annex 1 will likely have a significant impact on your CCI testing practices. In this webinar CCI testing strategies and the proposed revisions to EU Annex 1 are discussed.

Increased regulatory scrutiny and exciting new analytical technologies have altered the landscape of container closure integrity testing. In order to provide guidance to this new environment the US Pharmacopoeia revised Chapter <1207> Sterile Product Package Integrity.  View this webinar recording to learn about the new guidelines and how they will impact your approach to sterile product package integrity.

Dr. Derek Duncan, Director of Product Lines, Lighthouse Instruments, covers approaches that can be used for method development for CCI testing in all phases of the product life cycle.

Watch to gain a comprehensive understanding of water activity testing as well as how to effectively use non-destructive headspace analysis to generate dependable water activity data.

Learn how to interpret the Annex 1 container closure requirements, develop deterministic analytical methods for CCIT, and design packaging studies that generate robust data demonstrating good CCI.

Learn about the advantages and disadvantages of CCI testing methods, how the revised EU Annex 1 may impact your strategy for ensuring CCI of sterile pharmaceutical products, and more.

Dr. Derek Duncan, Director of Product Lines, Lighthouse Instruments, and Brandon Zurawlow, Chief Scientific Officer, CS Analytical, discuss a program for generating packaging data for deep cold storage products.

APPLICATION NOTES

Learn how to comply with the new EU Annex 1 Section 8.28. Here, we describe a typical raised-stopper investigation and demonstrate how to generate scientifically robust data using headspace analysis.

Discover a collaborative automated sample handler that eliminates manual sample handling, enabling groups to test larger sample sets and collect statistically significant data while freeing up analysts’ time.

Here, we describe how rapid non-destructive headspace moisture determination enables the generation of insightful data for product life cycle activities.

If CCI is lost during -80°C storage, non-sterile, cold, dense gas from the storage environment (i.e. air from a -80°C freezer or carbon dioxide from dry ice) can leak into the stored vial. It is therefore critical that robust development work is done to understand the CCI performance of any primary packaging components used for product needing deep cold storage and transport temperatures.

Pharmaceutical formulations, especially delicate large molecule biopharmaceuticals, may have some level of oxygen-sensitivity leading to degradation of the active pharmaceutical ingredient. Laser-based headspace oxygen analysis enables accurate, efficient determination of oxygen consumption curves. Accurate measurement of the oxidation rate supports the determination of headspace oxygen specifications and end-of-shelf life stability.

Laser-based headspace provides yet another alternative approach for detecting microbial contamination in sterile pharmaceutical product allows for quicker, more sensitive, accurate, and reproducible test results when compared with conventional, growth-based methods.

This application note describes how laser-based headspace analysis is used for the rapid non-destructive determination of headspace oxygen levels in pre-filled syringes. Data is presented demonstrating two major applications of this technique: 1) headspace oxygen monitoring on a pre-filled syringe line filling oxygen-sensitive product, and 2) container closure testing of pre-filled syringes.

This app note describes the application of the PULSAR inspection platform to perform 100% headspace oxygen monitoring during the filling of oxygen-sensitive formulations, 100% container closure inspection of suspect batches, moisture inspection of freeze dried product, and automated media fill inspection.

Large molecule biopharmaceuticals can be prone to oxidation and to prevent this from occurring, the headspace is often purged with an inert gas during filling to ensure a longer shelf life.

Using a high sensitivity detection technique known as Frequency Modulation Spectroscopy (FMS), LIGHTHOUSE rapid non-destructive headspace oxygen inspection can help streamline the monitoring of purge performance on the filling line. This paper demonstrates the correlation of the FMS rapid non-destructive technique for analyzing headspace oxygen levels with the most commonly used conventional destructive techniques for headspace oxygen inspection.

CONTACT INFORMATION

Lighthouse Instruments

2030 Avon Court

Charlottesville, VA 22902

UNITED STATES

Phone: 434-293-3081

Contact: Sales

FEATURED APPLICATION NOTES

FEATURED CASE STUDIES

WHITE PAPERS

CASE STUDIES

FEATURED WEBINARS

  • Increased regulatory scrutiny and exciting new analytical technologies have altered the landscape of container closure integrity testing. In order to provide guidance to this new environment the US Pharmacopoeia revised Chapter <1207> Sterile Product Package Integrity.  View this webinar recording to learn about the new guidelines and how they will impact your approach to sterile product package integrity.

  • This webinar presents how to design and conduct studies to assess the total oxygen permeation rate of your pre-filled syringes, and how to determine if the permeation is primarily through the plunger or through the tip.  Protecting oxygen-sensitive formulations during filling will also be discussed. 

  • This webinar will review how oxygen levels in finished parenteral drug containers can be determined and controlled throughout the product life cycle by using laser-based headspace analysis.

  • This webinar describes how non-destructive headspace moisture analysis can be used for characterizing batch moisture distributions, for lyo cycle development and optimization, and for freeze dryer moisture mapping and validation.

  • Dr. Derek Duncan, Director of Product Lines, Lighthouse Instruments, covers approaches that can be used for method development for CCI testing in all phases of the product life cycle.

  • The new language in EU Annex 1 will likely have a significant impact on your CCI testing practices. In this webinar CCI testing strategies and the proposed revisions to EU Annex 1 are discussed.